Finding new drugs to fight Ebola by targeting a specific viral protein.
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly
['FUNDING_SBIR_1'] · OYAGEN, INC. · NIH-10904764
This study is looking for new medicines to help fight Ebola by testing a huge number of small compounds to see which ones can stop a key part of the virus from working, aiming to find quick treatments that can help patients during outbreaks.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OYAGEN, INC. (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10904764 on ClinicalTrials.gov |
What this research studies
This research focuses on developing antiviral treatments for Ebola by screening a large library of small molecules to identify those that can inhibit the Ebola VP40 protein, which is crucial for the virus's ability to replicate and spread. The approach involves high-content screening techniques that allow for the rapid testing of approximately 123,000 compounds to find effective antagonists. By targeting the VP40 protein, the goal is to create a fast-acting therapy that does not rely on the immune system, potentially improving survival rates for patients during outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are infected with the Ebola virus or are at high risk during an outbreak.
Not a fit: Patients who are not infected with the Ebola virus or those who do not live in outbreak regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a new antiviral therapy that significantly improves survival rates for Ebola patients.
How similar studies have performed: Previous research has shown promise in targeting viral proteins for drug development, indicating that this approach could be effective.
Where this research is happening
ROCHESTER, UNITED STATES
- OYAGEN, INC. — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BENNETT, RYAN P — OYAGEN, INC.
- Study coordinator: BENNETT, RYAN P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.